Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FUROSEMIDE

All products: general benefit

Furosemide · DIN 02351420 · 20mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-06-05 — choose a marketed DIN from the same-category list.Discontinued 2024-06-05 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-06-05 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-06-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Furosemide · DIN 02351420 Manufacturer: Sanis Health Inc.; listing date 2020-10-30 Health Canada: Cancelled post market since 2024-06-05 · brand FUROSEMIDE · ATC C03CA01 FUROSEMIDE · form Tablet · route Oral · ingredients FUROSEMIDE 20 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Furosemide: Formulary list price $0.0218/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0218 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83669 · Verify on the e-Formulary ↗ (DIN 02351420)

Source record
DIN 02351420: Furosemide Raw flags: chronicUseMed=Y, sec3=Y Item: 402800019; group id 559; item number 1498; lccId None; manufacturer id SAI Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0218; ministry $0.0218 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02351420 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83669
Interchangeable products
Apo-Furosemide · DIN 00396788 · $0.0218 Lasix · DIN 02224690 · not recorded Mint-Furosemide · DIN 02466759 · $0.0218 Teva-Furosemide · DIN 00337730 · $0.0218
Shortage status: anticipated shortage (last updated 2026-03-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02351420
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-06-05 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (40:28 Diuretics) and how they are covered

Matched class: 40:28 Diuretics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMILORIDE HCL, METOLAZONE, SPIRONOLACTONE Some products covered without a code (check the product listing): AMILORIDE HCL & HYDROCHLOROTHIAZIDE, CHLORTHALIDONE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE & SPIRONOLACTONE, HYDROCHLOROTHIAZIDE & TRIAMTERENE, INDAPAMIDE 40:28 Diuretics

AMILORIDE HCL

· 1 products · General benefit · strengths: 5mg · Tab

AMILORIDE HCL & HYDROCHLOROTHIAZIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg & 50mg · Tab

CHLORTHALIDONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 50mg · Tab

HYDROCHLOROTHIAZIDE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (2), General benefit (7) · strengths: 12.5mg, 25mg, 50mg · Tab

HYDROCHLOROTHIAZIDE & SPIRONOLACTONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg & 25mg, 50mg & 50mg · Tab

HYDROCHLOROTHIAZIDE & TRIAMTERENE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg & 50mg · Tab

INDAPAMIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1.25mg, 2.5mg · Tab

METOLAZONE

· 1 products · General benefit · strengths: 2.5mg · Tab

SPIRONOLACTONE

· 8 products · General benefit · strengths: 25mg, 100mg · Tab

MIDODRINE HCL

· 10 products · Listed, not a benefit (2), Limited Use, codes 01 (8) · strengths: 2.5mg, 5mg · Tab

TOLVAPTAN

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 15mg & 15mg, 30mg & 15mg, 45mg & 15mg, 60mg & 30mg, 90mg & 30mg · 14-Tabs Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:28
Full class listing Related classes: 40:12 Replacement Agents, 40:18 Potassium-Removing Resins, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-FUROSEMIDE (furosemide) is indicated for:  The treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease including, nephrotic syndrome, as well as other edematous states amenable to diuretic therapy.  Can also be used alone in the control of mild to moderate hypertension, or in combination with other antihypertensive agents in more severe cases. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controllable with furosemide alone. 3 Pediatrics When administered to children, TEVA-FUROSEMIDE therapy should be instituted in the hospital, in carefully selected patients, under close observation with frequent monitoring of serum electrolytes (see DOSAGE AND ADMINISTRATION section). The available pediatric data does not allow for a recommendation of a specific age range in this population. Geriatrics (> 61 years of age) Use in the geriatric population is associated with differences in safety (see WARNINGS AND PRECAUTIONS). https://pdf.hres.ca/dpd_pm/00055547.PDF PM date: March 24, 2020 Source product: TEVA-FUROSEMIDE; DIN 00337730; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.